within Pharmacolibrary.Drugs.ATC.C;

model C03BA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03BA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Clofenamide is a diuretic drug from the sulfonamide family, historically used for the management of hypertension and edema associated with heart failure or renal disorders. It is not widely used today and is not approved or available in many countries due to the presence of safer and more effective alternatives.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models or human PK parameter data for clofenamide were identified in the literature or indexed pharmacokinetic databases as of 2024.</p><h4>References</h4><ol><li><p>Delbeke, FT, &amp; Debackere, M (1986). The influence of diuretics on the excretion and metabolism of doping agents. III. Etilamfetamine. <i>Arzneimittel-Forschung</i> 36(9) 1413–1416. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3790195/\">https://pubmed.ncbi.nlm.nih.gov/3790195</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03BA07;
